Search Results 1931-1940 of 20081 for Receptor
... receptor blockers. Recent change in medications that are known to affect IOP within 30 days prior to the screening visit and during the study including ...
Subjects who have taken or are currently taking any parenteral, inhaled, or oral prostacyclin or prostacyclin receptor agonists (e.g., epoprostenol ...
* Note: In Part A, prior exposure to anti g-protein-coupled receptor, class c, group 5, member d (GPRC5D) therapy and anti B-cell maturation antigen (BCMA) ...
... receptor blockers are allowed), CTLA4 inhibitors, and PD-1/PD-L1 inhibitors). * Ongoing chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) of ...
"We are able to identify molecular features, receptors and genetic markers. These patterns may offer clues as to how the tumor will respond to different ...
... receptor T-cell \[CAR-T\] directed against BCMA). Exclusion Criteria: - Arm A: Received BCMA-targeted therapy. Note: Other protocol defined Inclusion ...
I discovered LGI1 and CASPR2 antibodies, and have cared for over 300 patients with LGI1, CASPR2, NMDA, AQP4, MOG and GABA receptor-antibodies and ...
Uncontrolled blood glucose (including HbA1C >7 or metabolic crisis in past 60 days) or treatment with GLP-1 receptor agonist (e.g. dulaglutide, semaglutide ...
... receptors (TCRs) for assessment of immune repertoire diversity by iRepertoire®. Participation eligibility. Participant eligibility includes age, gender, type ...
Learn about these slow-growing cancers that usually begin in the digestive system or in the lungs. Treatments include peptide receptor radionuclide therapy.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.